What type of drug is Ajovy?
Medically reviewed by Judith Stewart, BPharm. Last updated on Oct 8, 2020.
People who suffer from migraine have increased levels of calcitonin gene‐related peptide (CGRP), a neuropeptide present in the nervous system. When CGRP binds to its receptor, it results in a cascade of events that contribute to the inflammation associated with migraine pain. Ajovy selectively targets the CGRP ligand and blocks its binding to the receptor, blocking this cascade of events and preventing a migraine attack.
Three other CGRP antagonists have been approved:
- Aimovig (erenumab-aooe) was the first approved CGRP antagonist. Aimovig binds potently and selectively to the CGRP receptor (not the ligand) to block CGRP activation, thereby preventing migraine pain.
- Emgality (galcanezumab-gnlm) has a similar mechanism of action to Ajovy; it binds to the CGRP ligand and blocks its binding to the receptor to help prevent migraine pain.
- Vyepti (eptinezumab-jjmr) also binds to the CGRP ligand and blocks its binding to the receptor.
Related Medical Questions
- Ajovy vs Aimovig: What's the difference between them?
- What are the new drugs for the treatment and prevention of migraine?
- Does Ajovy cause weight gain?
- How long does it take for Ajovy to start working?
- What is the cost of the migraine drug Ajovy?
- How does Ajovy work for migraines?
- How do you use the migraine drug Ajovy?